The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index

It is a pleasure to report that the Sage Therapeutics, Inc. (NASDAQ:SAGE) is up 50% in the last quarter. But that...

Wedbush analyst Laura Chico upgraded Sage Therapeutics to outperform on the potential of a developmental drug to treat depression.

Peloton and Oracle got a lift from better-than-expected earnings. Nikola took a massive hit as its CEO disputes fraud allegations.

Upgrades * According to Wedbush, the prior rating for Sage Therapeutics Inc (NASDAQ: SAGE) was changed from Neutral to Outperform. Sage Therapeutics earned $2.08 in the second quarter, compared to $3.28 in the year-ago quarter. The current stock performance of Sage Therapeutics shows a 52-week-high

Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

With depression rates up amid the economic and health crises, mental health should be treated like a physical illness, Sage Therapeutics CEO Jeff Jonas said on "Mad Money."

Sage Therapeutics ([[SAGE]] +5.2%) is up on double normal volume, although down over 6% from its intraday high of $57.98, on the heels of its pipeline update today. Highlights:Co. has developed a

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Podcasts, Stitcher and Spotify (click the highlighted links). The tech sector will be in focus again in the week ahead as investors gauge if short-term pandemic plays like Zscaler (ZS) Palo Alto Networks (PANW), Fortinet (FTNT), Zoom Video (ZM) and DocuSign (DOCU) are good for the longer haul

Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Morgan Stanley 18th Annual Global Healthcare Conference

Morgan Stanley maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and raises the price target from $85 to $87.

Investors may be overly concerned about the impact of the presidential election on health care stocks, analysts say.

Raymond James upgrades Sage Therapeutics (NASDAQ:SAGE) from Market Perform to Outperform and announces $70 price target.

Shares of Sage Therapeutics (NASDAQ:SAGE) were flat in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 36.59% over the past year to ($2.08), which beat the estimate of ($2.66).Revenue of $1,089,000 rose b

Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(2.63) per share which beat the analyst consensus estimate of $(2.66) by 1.13 percent. This is a 19.82 percent increase over losses of $(3.28) per share from

Today, Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results f

Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the 2020 W

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Monday, Aug

Q1 2020 SAGE Therapeutics Inc Earnings Call